Literature DB >> 15683522

A new dual-chamber pacing mode to minimize ventricular pacing.

Arnaud Savouré1, Gerd Fröhlig, Daniel Galley, Pascal Defaye, Sylvain Reuter, Philippe Mabo, Nicolas Sadoul, Amel Amblard, Marcel Limousin, Frederic Anselme.   

Abstract

Despite the low long-term incidence of high-degree atrioventricular (AV) block and the known negative effects of ventricular pacing, programming of the AAI mode in patients with sinus node dysfunction (SND) remains exceptional. A new pacing mode was, therefore, designed to combine the advantages of AAI with the safety of DDD pacing. AAIsafeR behaves like the AAI mode in absence of AV block. First- and second-degree AV blocks are tolerated up to a predetermined, programmable limit, and conversion to DDD takes place in case of high-degree AV block. From DDD, the device may switch back to AAI, provided AV conduction has returned. The safety of AAIsafeR was examined in 43 recipients (70 +/- 12-year old, 24 men) of dual chamber pacemakers implanted for SND or paroxysmal AV block. All patients underwent 24-hour ambulatory electrocardiographic recordings before hospital discharge and at 1 month of follow-up with the AAIsafeR mode activated. No AAIsafeR-related adverse event was observed. At 1 month, the device was functioning in AAIsafeR in 28 patients (65%), and the mean rate of ventricular pacing was 0.2%+/- 0.4%. Appropriate switches to DDD occurred in 15 patients (35%) for frequent, unexpected AV block. AAIsafeR mode was safe and preserved ventricular function during paroxysmal AV block, while maintaining a very low rate of ventricular pacing. The performance of this new pacing mode in the prevention of atrial fibrillation will be examined in a large, controlled study.

Entities:  

Mesh:

Year:  2005        PMID: 15683522     DOI: 10.1111/j.1540-8159.2005.00095.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  8 in total

1.  [Pacemaker ECG quiz no. 21: Strange ECG after DDDR pacemaker implantation].

Authors:  C W Israel
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2010-03

2.  Reduction of right ventricular pacing in patients with sinus node dysfunction through programming a long atrioventricular delay along with the DDIR mode.

Authors:  Aischa Nitardy; Holger Langreck; Rainer Dietz; Martin Stockburger
Journal:  Clin Res Cardiol       Date:  2008-10-13       Impact factor: 5.460

3.  [Avoidance of ventricular pacing in patients with sinus node disease or intermittent AV block].

Authors:  U K H Wiegand
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2008-03

4.  Non-physiological increase of AV conduction time in sinus disease patients programmed in AAIR-based pacing mode.

Authors:  Philippe Mabo; Jean-Pierre Cebron; Aude Solnon; Aude Tassin; Laurence Graindorge; Daniel Gras
Journal:  J Interv Card Electrophysiol       Date:  2012-07-27       Impact factor: 1.900

Review 5.  Clinical outcomes with biventricular versus right ventricular pacing in patients with atrioventricular conduction defects.

Authors:  Dasheng Lu; Hongxiang Zhang; Chu Chen; Kai Wang; Qijun Shan
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

6.  Very Low Ventricular Pacing Rates Can Be Achieved Safely in a Heterogeneous Pacemaker Population and Provide Clinical Benefits: The CANadian Multi-Centre Randomised Study-Spontaneous AtrioVEntricular Conduction pReservation (CAN-SAVE R) Trial.

Authors:  Bernard Thibault; Anique Ducharme; Adrian Baranchuk; Marc Dubuc; Katia Dyrda; Peter G Guerra; Laurent Macle; Blandine Mondésert; Léna Rivard; Denis Roy; Mario Talajic; Jason Andrade; Rémi Nitzsché; Paul Khairy
Journal:  J Am Heart Assoc       Date:  2015-07-23       Impact factor: 5.501

7.  Ventricular pacing: to pace or not to pace.

Authors:  Paul A Levine
Journal:  Europace       Date:  2010-01       Impact factor: 5.214

8.  Long-term clinical effects of ventricular pacing reduction with a changeover mode to minimize ventricular pacing in a general pacemaker population.

Authors:  Martin Stockburger; Serge Boveda; Javier Moreno; Antoine Da Costa; Robert Hatala; Johannes Brachmann; Christian Butter; Javier Garcia Seara; Mara Rolando; Pascal Defaye
Journal:  Eur Heart J       Date:  2014-09-01       Impact factor: 29.983

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.